4.2 Article

Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis

Journal

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijporl.2008.12.025

Keywords

Mometasone furoate; Allergic rhinitis; Intranasal corticosteroids; Long-term safety

Funding

  1. Schering-Plough Research Institute
  2. Schering-Plough Corporation

Ask authors/readers for more resources

Objective: Perennial allergic rhinitis (PAR) affects children at a Young age. Current guidelines recommend intranasal corticosteroids as the first-line treatment in patients with moderate-to-severe or persistent disease or in those who have congestion. In this study, the long-term safety and efficacy of mometasone furoate nasal spray (MFNS) were assessed in children with PAR. Methods: In this multicenter, active-controlled, evaluator-blind, 12-month study, 255 children aged 611 years with a >= 1-year history of PAR were randomized to receive once-daily MFNS 100 mu g (n = 166) or the active comparator beclomethasone dipropionate (BDP) 168 mu g (n = 85). Changes from baseline in overall PAR symptoms and response to treatment were rated at each visit. Cosyntropin stimulation testing, as well as tonometry and slit lamp procedures, were performed. Safety variables were assessed. Results: A total of 137 subjects in the MFNS group and 68 in the BDP group completed treatment. The mean reductions in physician-and subject-rated overall condition of PAR at week 52 were -42.1% and -39.7%, respectively, for MFNS, compared with -44.0% and -39.0%, respectively, for BDP. A total of 94% and 100% of MFNS and BDP subjects, respectively, reported adverse events (AEs), which were mostly mild or moderate. The most frequently reported treatment-related AEs in both groups were epistaxis, headache, and pharyngitis. Response to cosyntropin was normal and no posterior subcapsular cataracts were observed in either group. Although no significant changes in intraocular pressure were observed with MFNS, one subject receiving BDP demonstrated this effect. Conclusions: Treatment with MFNS 100 mu g once daily for 1 year was well tolerated in children 6-11 years old, with negligible systemic exposure and no evidence of suppression of the hypothalamic-pituitary-adrenal axis or ocular changes. (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available